311 related articles for article (PubMed ID: 27605400)
21. Chemotherapy induces enhanced procoagulant activity through phosphatidylserine exposure in acute lymphoblastic leukemia.
Dong X; Shi J; Zhou J; Chen X; Jin Y; Zhang X; Li X; Dai H; Wang J
Thromb Res; 2013 Nov; 132(5):614-20. PubMed ID: 24074703
[TBL] [Abstract][Full Text] [Related]
22. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
[TBL] [Abstract][Full Text] [Related]
23. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
24. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
25. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Chen J; Ngo D; Aldoss I; Shayani S; Tsai NC; Pullarkat V
Leuk Lymphoma; 2019 May; 60(5):1187-1192. PubMed ID: 30322332
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ribera JM; Morgades M; Montesinos P; Martino R; Barba P; Soria B; Bermúdez A; Moreno MJ; González-Campos J; Vives S; Gil C; Abella E; Guàrdia R; Martínez-Carballeira D; Martínez-Sánchez P; Amigo ML; Mercadal S; Serrano A; López-Martínez A; Vall-Llovera F; Sánchez-Sánchez MJ; Peñarrubia MJ; Calbacho M; Méndez JA; Bergua J; Cladera A; Tormo M; García-Belmonte D; Feliu E; Ciudad J; Orfao A;
Leuk Lymphoma; 2018 Jul; 59(7):1634-1643. PubMed ID: 29165013
[TBL] [Abstract][Full Text] [Related]
27. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
28. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
[TBL] [Abstract][Full Text] [Related]
29. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
30. Clofarabine in combination with pegylated asparaginase in the frontline treatment of childhood acute lymphoblastic leukaemia: a feasibility report from the CoALL 08-09 trial.
Escherich G; Zur Stadt U; Zimmermann M; Horstmann MA;
Br J Haematol; 2013 Oct; 163(2):240-7. PubMed ID: 23937310
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the anticoagulant effect of a direct thrombin inhibitor and a low molecular weight heparin in an acquired antithrombin deficiency in children with acute lymphoblastic leukaemia treated with L-asparaginase: an in vitro study.
Kuhle S; Lau A; Bajzar L; Vegh P; Halton J; Cherrick I; Anderson R; Desai S; McCusker P; Wu J; Abshire T; Mahoney D; Mitchell L
Br J Haematol; 2006 Sep; 134(5):526-31. PubMed ID: 16856890
[TBL] [Abstract][Full Text] [Related]
32. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia.
Andrew M; Brooker L; Mitchell L
Blood Coagul Fibrinolysis; 1994 Jan; 5 Suppl 1():S24-36; discussion S59-64. PubMed ID: 8186353
[TBL] [Abstract][Full Text] [Related]
33. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
34. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia.
Ranta S; Heyman MM; Jahnukainen K; Taskinen M; Saarinen-Pihkala UM; Frisk T; Söderhäll S; Petrini P; Mäkipernaa AM
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):749-56. PubMed ID: 24056293
[TBL] [Abstract][Full Text] [Related]
35. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
Liu L; Xie XT
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
[TBL] [Abstract][Full Text] [Related]
36. Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes.
Uszyński M; Osińska M; Zekanowska E; Ziółkowska E
Med Sci Monit; 2000; 6(1):108-11. PubMed ID: 11208295
[TBL] [Abstract][Full Text] [Related]
37. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
38. Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin-Frankfurt-Münster (BFM) protocols.
Lejhancova-Tousovska K; Zapletal O; Vytiskova S; Strbackova P; Sterba J
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):144-54. PubMed ID: 22227959
[TBL] [Abstract][Full Text] [Related]
39. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
[TBL] [Abstract][Full Text] [Related]
40. Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
Helbig G; Armatys A; Boral K; Kopinska AJ; Wozniczka K; Dworaczek M; Chromik K; Koclega A; Panz-Klapuch M; Wysocka M; Janikowska A
Neoplasma; 2018 Nov; 65(6):993-997. PubMed ID: 29940768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
